ARF1 and cancer: Although ARF1 has several favorable characteristics, i.e., crystal structure and inhibitors effective against both Plasmodium and cancer cells65–67, computational prediction and experimental validation are needed to identify effective Plasmodium inhibitors since a druggability challenge with small GTPases is the displacement of GTP binding.